Tom 7, Nr 5 (2021)
Artykuł przeglądowy
Opublikowany online: 2021-11-25
Wyświetlenia strony
3281
Wyświetlenia/pobrania artykułu
319
Czerniak skóry i błon śluzowych
Onkol Prakt Klin Edu 2021;7(5):339-345.
Streszczenie
Wprowadzenie przeciwciał anty-CTLA4 (ipilimumab) i anty-PD1 (niwolumab, pembrolizumab) do pratyki klinicznej znacząco poprawiło rokowanie chorych na czerniaka. Immunoterapia istotnie poprawia przeżycia całkowite chorych na czerniaka w stadium rozsiewu oraz przeżycia wolne od nawrotu choroby u chorych na resekcyjnego czerniaka o wysokim ryzyku nawrotu. Leczenie immunomodulujące przyniosło jednak szeroki wachlarz działań niepożądanych o podłożu autoimmunologicznym. Szybkie ich rozpoznanie i wdrożenie odpowiedniego leczenia są kluczowe dla dalszego postępowania terapeutycznego oraz jakości życia chorych. Celem niniejszej pracy jest przedstawienie zarówno ugruntowanych już terapii, jak i nowych obiecujących kierunków dalszego rozwoju immunoterapii.
Słowa kluczowe: czerniak skóryczerniak błon śluzowychimmunoterapia
Referencje
- Haanen JB, Robert C. Immune Checkpoint Inhibitors. Prog Tumor Res. 2015; 42: 55–66.
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med. 2010; 363(13): 1290–1290.
- Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. N Engl J Med. 2011; 364(26): 2517–2526.
- Maio M, Lewis K, Demidov L, et al. BRIM8 Investigators. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2017; 18(5): 611–622.
- Cybulska-Stopa B, Rogala P, Czarnecka AM, et al. Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence. Adv Med Sci. 2020; 65(2): 316–323.
- Silva IP, Ahmed T, Lo S, et al. Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy. J Clin Oncol. 2020; 38(15_suppl): 10005–10005.
- Robert C, Schachter J, Long G, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015; 372(26): 2521–2532.
- Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019; 20(9): 1239–1251.
- Weber J, D'Angelo S, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015; 16(4): 375–384.
- Larkin J, Minor D, D'Angelo S, et al. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. J Clin Oncol. 2018; 36(4): 383–390.
- Robert C, Long G, Brady B, et al. Nivolumab in Previously Untreated Melanoma withoutBRAFMutation. Lancet Oncol. 2015; 372(4): 320–330.
- Ascierto PA, Long GV, Robert C, et al. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. JAMA Oncol. 2019; 5(2): 187–194.
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015; 373(13): 1270–1271.
- Wolchok J, Chiarion-Sileni V, Gonzalez R, et al. CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma. J Clin Oncol. 2021; 39(15_suppl): 9506–9506.
- Lipson EJ, et al. Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047)Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047). 2021.
- Chang A, Karnell L, Menck H. The National Cancer Data Base report on cutaneous and noncutaneous melanoma. Cancer. 1998; 83(8): 1664–1678, doi: 10.1002/(sici)1097-0142(19981015)83:8<1664::aid-cncr23>3.0.co;2-g.
- Hamid O, Robert C, Ribas A, et al. Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. Br J Cancer. 2018; 119(6): 670–674.
- Shoushtari A, Wagstaff J, Ascierto P, et al. CheckMate 067: Long-term outcomes in patients with mucosal melanoma. J Clin Oncol. 2020; 38(15_suppl): 10019–10019.
- Teterycz P, Czarnecka AM, Indini A, et al. Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy. Cancers (Basel). 2020; 12(11).
- Eggermont A, Blank C, Mandala M, et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med. 2018; 378(19): 1789–1801.
- Eggermont AMM, Blank CU, Mandala M, et al. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. J Clin Oncol. 2020; 38(33): 3925–3936.
- Weber J, Mandala M, Vecchio MD, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017; 377(19): 1824–1835.
- Ascierto P, Vecchio MD, Mandalá M, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2020; 21(11): 1465–1477.
- Rozeman E, Menzies A, Akkooi Av, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 2019; 20(7): 948–960.
- Sznol M, Ferrucci PF, Hogg D, et al. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. J Clin Oncol. 2017; 35(34): 3815–3822.
